Activated platelet surface and platelet-derived microparticles (PMP)

Activated platelet surfaces and platelet-derived microparticles (PMPs) represent a specialized procoagulant and pro-inflammatory environment essential for vascular integrity and response to injury [Source: PubMed PMID: 24856238]. Upon activation by agonists such as thrombin or collagen, platelets undergo a dramatic transformation, exposing anionic phospholipids like phosphatidylserine (PS) and shedding PMPs, which are small vesicles ranging from 0.1 to 1.0 micrometers in diameter [Source: PubMed PMID: 10506062]. These surfaces serve as catalytic platforms for the assembly of coagulation factor complexes (tenase and prothrombinase), significantly accelerating thrombin generation [Source: PubMed PMID: 9330217]. Furthermore, they express high levels of adhesion molecules like P-selectin (CD62P) and integrin alpha-IIb/beta-3, facilitating critical interactions with leukocytes and endothelial cells during inflammation [Source: UniProt P16109]. In pathological states, an excess of PMPs and persistently activated platelet surfaces contribute to arterial and venous thrombosis, the progression of atherosclerosis, and the hematogenous spread of cancer cells [Source: PubMed PMID: 21829458]. Therapeutic targeting of these entities involves using monoclonal antibodies like Crizanlizumab to block P-selectin or utilizing the unique lipid composition for targeted drug delivery and diagnostic imaging of active clots.

Other names

Platelet-derived microvesiclesPlatelet dustActivated platelet membraneProcoagulant platelet surfacePlatelet-derived extracellular vesicles

Blockade of surface adhesion molecules (e.g., P-selectin, GPIIb/IIIa) and neutralization of procoagulant phosphatidylserine exposure to prevent thrombus formation and inflammatory signaling.